SCHEMBL117343

SCHEMBL117343

CC(C)(C)c1ccc(-n2cccn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.58
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPK1 P28482 1/20 0.53
BRS3 P32247 3/20 0.48
CHRNA7 P36544 1/20 0.45
CHRNA10 Q9GZZ6 1/20 0.45
CHRNA9 Q9UGM1 1/20 0.45
GCGR P47871 1/20 0.43
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
POLB P06746 1/20 0.40
MGLL Q99685 1/20 0.40
TP53 P04637 1/20 0.40
KIF11 P52732 1/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341894 0.83 NOTUM (0.78) NOTUMKDM4EALDH1A1MAPK1CHRNA7
SCHEMBL3871686 0.82 GCGR (0.59) KDM4EALDH1A1MAPK1GCGRMAPT
SCHEMBL3318259 0.81 NOTUM (0.58) NOTUMKDM4EALDH1A1MAPK1BRS3
SCHEMBL4406625 0.80 NOTUM (0.44) NOTUMKDM4EALDH1A1MAPK1MAPT
SCHEMBL19592843 0.80 NOTUM (0.49) NOTUMKDM4EALDH1A1MAPK1BRS3
SCHEMBL27777477 0.80 KDM4E (0.57) NOTUMKDM4EALDH1A1MAPK1BRS3
SCHEMBL3831000 0.79 BRS3 (0.50) NOTUMKDM4EALDH1A1MAPK1BRS3
SCHEMBL82721 0.78 NOTUM (0.64) NOTUMKDM4EALDH1A1MAPK1CHRNA7
SCHEMBL22013501 0.77 BRS3 (0.49) NOTUMKDM4EALDH1A1MAPK1BRS3
SCHEMBL20201255 0.77 NOTUM (0.53) NOTUMKDM4EALDH1A1MAPK1BRS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1218472-A Pharmaceutically useful compounds ASTRA PHARMA PROD (GB) 1999-06-02 CN claimed
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS UNIVERSITÉ PARIS CITÉ (FR) 2025-01-30 US disclosed
US-11746116-B2 Antibiotic resistance breakers KING'S COLLEGE LONDON (GB) 2023-09-05 US disclosed
US-11746116-B2 Antibiotic resistance breakers KING'S COLLEGE LONDON (GB) 2023-09-05 US disclosed
US-20230136177-A1 IMMUNOMODULATING O-HET/ARYL AZALIDES ZOETIS SERVICES LLC 2023-05-04 US disclosed
US-20230136177-A1 IMMUNOMODULATING O-HET/ARYL AZALIDES ZOETIS SERVICES LLC 2023-05-04 US disclosed
US-20230129040-A1 IMMUNOMODULATING AZALIDES ZOETIS SERVICES LLC 2023-04-27 US disclosed
US-20230129040-A1 IMMUNOMODULATING AZALIDES ZOETIS SERVICES LLC 2023-04-27 US disclosed
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20070185130-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds ROSKAMP RESEARCH LLC 2007-08-09 US disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed
US-20070037855-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds ALZHEIMER'S INSTITUTE OF AMERICA, INC. 2007-02-15 US disclosed
US-20070037855-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds ALZHEIMER'S INSTITUTE OF AMERICA, INC. 2007-02-15 US disclosed
EP-1244446-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2006-11-02 EP disclosed
US-6858630-B2 Naphthimidazole derivatives and their use as thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2005-02-22 US disclosed
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-05-01 US disclosed
EP-1244446-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2003-01-08 EP disclosed
EP-1244446-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-10-02 EP disclosed
WO-2001039773-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083361-A1 Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia MPL, THPO, TPO NOTUM 3916/4885KDM4E 4286/4885ALDH1A1 2193/4885
US-11746116-B2 Antibiotic resistance breakers ABCC1, ARL1, AKR1C3 NOTUM 4616/4885KDM4E 3599/4885ALDH1A1 481/4885
US-20070185130-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds APP, PSEN1, PSEN2 NOTUM 2693/4885KDM4E 4759/4885ALDH1A1 3939/4885
US-20070037855-A1 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds APP, PSEN1, PSEN2 NOTUM 2693/4885KDM4E 4759/4885ALDH1A1 3939/4885
US-20230129040-A1 IMMUNOMODULATING AZALIDES IL2, MALT1, FCGRT NOTUM 3729/4885KDM4E 646/4885ALDH1A1 196/4885
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL NOTUM 507/4885KDM4E 4358/4885ALDH1A1 648/4885
US-20230136177-A1 IMMUNOMODULATING O-HET/ARYL AZALIDES IL2, MALT1, IL2RA NOTUM 3096/4885KDM4E 652/4885ALDH1A1 276/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL NOTUM 507/4885KDM4E 4358/4885ALDH1A1 648/4885
US-20250034127-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS SQSTM1, TFEB, BECN1 NOTUM 4188/4885KDM4E 2987/4885ALDH1A1 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.